William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy.

Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies. Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins. Dr. Imus is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Dr. Webster is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Webster has expertise in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Dr. Webster received his medical degree from The Stanford University School of Medicine. He completed residency training in internal medicine at Johns Hopkins followed by a fellowship in medical oncology. He completed the Science of Clinical Investigation curriculum at the Johns Hopkins Bloomberg School of Public health. Dr. Webster is a member of the American Society of Hematology, and the American Society of Clinical Oncology. Dr. Webster’s research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of acute leukemias (ALL and AML). He has specific expertise in the use of maintenance therapies following bone marrow transplantation. He has developed novel clinical trials utilizing immunotherapy for the treatment of ALL and the prevention of post-transplant relapse in both ALL and AML. He serves as the Principal Investigator for these trials of post-transplant maintenance strategies, as well as the site PI for multi-center trials that are currently being conducted through the Eastern Co-operative Oncology Group (ECOG)-ACRIN and Experimental Therapeutics Clinical Trials Network (ETCTN). As the leader of the adult ALL program at Johns Hopkins, he has focused on increasing clinical trial enrollments and improving outcomes in adult ALL. Dr. Webster is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Christian Gocke is a Hematologist in Baltimore, Maryland. Dr. Gocke is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Bone Marrow Transplant.

Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma.

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

Seung Lee is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Jennie Law is a Hematologist Oncology specialist and a Hospital Medicine provider in Baltimore, Maryland. Dr. Law is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, Hemoglobin E Disease, and Bone Marrow Aspiration. Dr. Law is currently accepting new patients.

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and T-Cell Lymphoma.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer.

Carole Miller is an Oncologist in Baltimore, Maryland. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer. Dr. Miller is currently accepting new patients.